Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting
Disease and Therapeutics · 2026 · 2 · 100012
DOI: 10.1016/j.dist.2026.100012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease and Therapeutics, 2026. Verfasst von Shivani Sharma und 8 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 275 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Background
Chimeric Antigen Receptor (CAR)-T cell therapy has demonstrated remarkable clinical success in hematological malignancies; however, its translation to solid tumors remains limited due to the hostile tumor microenvironment (TME), characterized by physical barriers, immunosuppression, metabolic competition, and treatment-limiting toxicities such as Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Purpose
This review aims to critically evaluate next-generation combination strategies that enhance CAR-T efficacy in solid tumors, with particular emphasis on phytochemicals and natural small molecules as immunometabolic modulators within multimodal therapeutic frameworks. Study Design This is a narrative and mechanism-oriented review integrating evidence from immunotherapy, pharmacology, nanomedicine, and computational biology.
Methods
Relevant literature was systematically examined to analyze emerging approaches that combine CAR-T therapy with nanotechnology-enabled delivery systems, phytochemical-based metabolic modulation, and artificial intelligence-driven network pharmacology. Mechanistic pathways including AMPK-mTOR-SIRT1 signaling, NF-κB activation, STAT3 signaling, and NLRP3 inflammasome regulation were evaluated in the context of CAR-T persistence, metabolic fitness, and toxicity mitigation.
Results
Evidence indicates that localized nanotechnology platforms such as “backpack” nanoparticles improve CAR-T trafficking and reduce systemic toxicity. Phytochemicals including resveratrol, berberine, curcumin, and baicalin function as metabolic regulators that promote mitochondrial fitness, shift T-cell metabolism toward oxidative phosphorylation, and attenuate hyperinflammatory signaling underlying CRS. Artificial intelligence and network pharmacology approaches further enable rational identification of synergistic combinations and predictive responder stratification.
Conclusion
Multimodal precision strategies integrating nanotechnology, phytochemical immunometabolic modulation, and computational design represent promising avenues to overcome solid tumor resistance to CAR-T therapy. Repositioning natural small molecules as mechanistic immunopharmacological adjuvants may enhance therapeutic durability while reducing toxicity, supporting their translational potential in solid tumor immunotherapy.
Förderung
- Science and Engineering Research Board
Zitieren
APA
Sharma, S., Saha, S., Arora, S., Ahlawat, Y. K., Sheoran, S., Mukherjee, S., Sinha, A., Chaudhary, K., & Gosipatala, S. B. (2026). Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting. Disease and Therapeutics, 2, 100012. https://doi.org/10.1016/j.dist.2026.100012
Vancouver
Sharma S, Saha S, Arora S, Ahlawat YK, Sheoran S, Mukherjee S, et al. Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting. Disease and Therapeutics. 2026;2:100012. doi:10.1016/j.dist.2026.100012
BibTeX
@article{Sharma2026,
author = {Sharma, Shivani and Saha, Sobin and Arora, Swati and Ahlawat, Yogesh K. and Sheoran, Sumit and Mukherjee, Srestha and Sinha, Astha and Chaudhary, Kirti and Gosipatala, Sunil Babu},
title = {Next-generation CAR-T combinations: Integrating nanomedicine, metabolic reprogramming, and AI for solid tumor targeting},
journal = {Disease and Therapeutics},
year = {2026},
volume = {2},
pages = {100012},
doi = {10.1016/j.dist.2026.100012}
}
EUVIMED